What is it about?
This article discusses the change in myoglobin (MYO) in HHS and DKA, which is associated with the outcome of patients. In addition, we linked the various sources of MYO with the outcomes of patients, the type of diabetes, and different genders, and revealed different survival rates.
Featured Image
Photo by Aziz Acharki on Unsplash
Why is it important?
Because DKA and HHS are acute, severe complications of diabetes, this article helps physicians judge the sources of MYO that may become in HHS and DKA and provides possible relationships with patient outcomes. Through the analyses, we may use MYO combined with its source to acknowledge patients' conditions and take early action.
Perspectives
Though the MYO is not a specific biomarker of cardiovascular diseases, it can also help physicians to monitor a patient' progress in severe conditions.
Dr. Song Wen
Shanghai Pudong Hospital
Read the Original
This page is a summary of: The Implication of Elevated Serum Myoglobin Level in Acute Diabetic Complications of Ketoacidosis and Hyperglycemic Hyperosmolar State: A Real-World Study, Diabetes Metabolic Syndrome and Obesity, July 2024, Taylor & Francis,
DOI: 10.2147/dmso.s465311.
You can read the full text:
Resources
Contributors
The following have contributed to this page
